About biomx inc - PHGE
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
PHGE At a Glance
BiomX, Inc.
850 New Burton Road
Dover, Delaware 19904
| Phone | 972-54-561-0935 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -36,199,000.00 | |
| Sector | Health Technology | Employees | 20 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PHGE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.605 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.079 |
PHGE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,809,950.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PHGE Liquidity
| Current Ratio | 0.874 |
| Quick Ratio | 0.874 |
| Cash Ratio | 0.777 |
PHGE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -42.827 |
| Return on Equity | -316.896 |
| Return on Total Capital | -27,014.179 |
| Return on Invested Capital | -231.304 |
PHGE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,071.642 |
| Total Debt to Total Assets | 2.044 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |